Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Bladder Cancer, December 2017

Free Subscription


Abstracts

Retrieve all available abstracts of the following 82 articles:
HTML format


 

Single Articles

  1. SUI X, Lei L, Chen L, Xie T, et al
    Inflammatory microenvironment in the initiation and progression of bladder cancer.
    Oncotarget. 2017;8:93279-93294.
    Abstract    

    Abstract available

  2. HOU T, Zhou L, Wang L, Kazobinka G, et al
    CLCA4 inhibits bladder cancer cell proliferation, migration, and invasion by suppressing the PI3K/AKT pathway.
    Oncotarget. 2017;8:93001-93013.
    Abstract    

    Abstract available

  3. WANG F, Wu D, Fu H, He F, et al
    Cofilin 1 promotes bladder cancer and is regulated by TCF7L2.
    Oncotarget. 2017;8:92043-92054.
    Abstract    

    Abstract available

  4. IMAI-SUMIDA M, Chiyomaru T, Majid S, Saini S, et al
    Silibinin suppresses bladder cancer through down-regulation of actin cytoskeleton and PI3K/Akt signaling pathways.
    Oncotarget. 2017;8:92032-92042.
    Abstract    

    Abstract available

  5. ZAGHLOUL MS, Christodouleas JP, Smith A, Abdallah A, et al
    Adjuvant Sandwich Chemotherapy Plus Radiotherapy vs Adjuvant Chemotherapy Alone for Locally Advanced Bladder Cancer After Radical Cystectomy: A Randomized Phase 2 Trial.
    JAMA Surg. 2017 Nov 29:e174591. doi: 10.1001/jamasurg.2017.4591.
    Abstract    

    Abstract available

  6. DIAZ DA, Mortazavi A, Lee CT
    A Potential Role for Adjuvant Chemotherapy and Radiotherapy for Patients With High-Risk Bladder Cancer Treated With Cystectomy in the United States.
    JAMA Surg. 2017 Nov 29:e174592. doi: 10.1001/jamasurg.2017.4592.
    Abstract    



  7. SOURAKA TDM, Shi MJ, Meng XY
    [The relationship between tumor recurrence and polymorphisms of hGPX1 and NRAMP1 in superficial bladder cancer patients: a meta-analysis].
    Pan Afr Med J. 2017;27:270.
    Abstract    

    Abstract available

  8. ZHANG Q, Zhuang J, Deng Y, Yang L, et al
    miR34a/GOLPH3 Axis abrogates Urothelial Bladder Cancer Chemoresistance via Reduced Cancer Stemness.
    Theranostics. 2017;7:4777-4790.
    Abstract    

    Abstract available


  9. Three more immune checkpoint inhibitors for advanced bladder cancer.
    Med Lett Drugs Ther. 2017;59:e202-e203.
    Abstract    



  10. BENACKA M, Benamran DA, Wirth G, Iselin CE, et al
    [Intravesical microwave thermo-chemotherapy for the treatment of non-invasive bladder cancer].
    Rev Med Suisse. 2017;13:2087-2091.
    Abstract    

    Abstract available

  11. ADAM SM, Derre L, Jichlinski P, Lucca I, et al
    [Immunotherapy : a revolution in the management of urothelial bladder cancer ?]
    Rev Med Suisse. 2017;13:2074-2078.
    Abstract    

    Abstract available

  12. MATSUMOTO A, Nakagawa T, Kanatani A, Ikeda M, et al
    Preoperative chronic kidney disease is predictive of oncological outcome of radical cystectomy for bladder cancer.
    World J Urol. 2017 Nov 28. pii: 10.1007/s00345-017-2141.
    Abstract    

    Abstract available

  13. BREYER J
    Improving outcome and prognosis prediction in non-muscle invasive bladder cancer using a gene expression score.
    Transl Androl Urol. 2017;6:991-993.
    Abstract    



  14. LUCHINI C, Cheng L
    Predicting the biological behavior of non-muscle-invasive bladder cancer: from histology to molecular taxonomy.
    Transl Androl Urol. 2017;6:987-990.
    Abstract    



  15. GALSKY MD
    Bladder cancer in 2017: Advancing care through genomics and immune checkpoint blockade.
    Nat Rev Urol. 2017 Nov 28. pii: nrurol.2017.199. doi: 10.1038/nrurol.2017.
    Abstract    



  16. TSIKRIKA FD, Avgeris M, Levis PK, Tokas T, et al
    miR-221/222 cluster expression improves clinical stratification of non-muscle invasive bladder cancer (TaT1) patients' risk for short-term relapse and progression.
    Genes Chromosomes Cancer. 2017 Nov 27. doi: 10.1002/gcc.22516.
    Abstract    

    Abstract available

  17. BANERJEE S, Manley K, Shaw B, Lewis L, et al
    Vigorous intensity aerobic interval exercise in bladder cancer patients prior to radical cystectomy: a feasibility randomised controlled trial.
    Support Care Cancer. 2017 Nov 27. pii: 10.1007/s00520-017-3991.
    Abstract    

    Abstract available

  18. CHEN J, Cui Y, Li P, Liu L, et al
    Expression and clinical significance of androgen receptor in bladder cancer: A meta-analysis.
    Mol Clin Oncol. 2017;7:919-927.
    Abstract    

    Abstract available

  19. DONG F, Shen Y, Gao F, Xu T, et al
    Prognostic value of site-specific metastases and therapeutic roles of surgery for patients with metastatic bladder cancer: a population-based study.
    Cancer Manag Res. 2017;9:611-626.
    Abstract    

    Abstract available

  20. YU G, Ou ZY, Tao QY, Wan GY, et al
    [Role of lncRNA PTENP1 in tumorigenesis and progression of bladder cancer and the molecular mechanism].
    Nan Fang Yi Ke Da Xue Xue Bao. 2017;37:1494-1500.
    Abstract    

    Abstract available

  21. WILLIAMS SB, Kamat AM, Mmeje C, Ye Y, et al
    Genetic variants in the inflammation pathway as predictors of recurrence and progression in non-muscle invasive bladder cancer treated with Bacillus Calmette-Guerin.
    Oncotarget. 2017;8:88782-88791.
    Abstract    

    Abstract available

  22. CAO R, Wang G, Qian K, Chen L, et al
    TM4SF1 regulates apoptosis, cell cycle and ROS metabolism via the PPARgamma-SIRT1 feedback loop in human bladder cancer cells.
    Cancer Lett. 2017 Nov 23. pii: S0304-3835(17)30733.
    Abstract    

    Abstract available

  23. CAMARGO JA, Passos GR, Ferrari KL, Billis A, et al
    Intravesical Immunomodulatory Imiquimod Enhances Bacillus Calmette-Guerin Downregulation of Nonmuscle-invasive Bladder Cancer.
    Clin Genitourin Cancer. 2017 Nov 7. pii: S1558-7673(17)30335.
    Abstract    

    Abstract available

  24. SUBIELA JD, Palou J, Esquinas C, Fernandez Gomez JM, et al
    Clinical usefulness of random biopsies in diagnosis and treatment of non-muscle invasive bladder cancer: Systematic review and meta-analysis.
    Actas Urol Esp. 2017 Nov 20. pii: S0210-4806(17)30196.
    Abstract    

    Abstract available

  25. LI X, Han X, Yang J, Sun J, et al
    [miR-503-5p inhibits the proliferation of T24 and EJ bladder cancer cells by interfering with the Rb/E2F signaling pathway].
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2017;33:1360-1364.
    Abstract    

    Abstract available

  26. YAMASHITA S, Ito A, Mitsuzuka K, Ioritani N, et al
    Efficacy of early ureteral ligation on prevention of intravesical recurrence after radical nephroureterectomy for upper urinary tract urothelial carcinoma: a prospective single-arm multicenter clinical trial.
    Jpn J Clin Oncol. 2017;47:870-875.
    Abstract    

    Abstract available

  27. FREIFELD Y, Lotan Y
    Value of nutrition supplementation prior to cystectomy.
    Can J Urol. 2017;24:8902.
    Abstract    



  28. ELBARBARY RA, Miyoshi K, Hedaya O, Myers JR, et al
    UPF1 helicase promotes TSN-mediated miRNA decay.
    Genes Dev. 2017;31:1483-1493.
    Abstract    

    Abstract available

  29. TUMA J, Serra A

    Praxis (Bern 1994). 2017;106:899-902.
    Abstract    



  30. FRASER C, Frizelle F
    A villous adenoma of bladder/urachus origin located in the perineum.
    N Z Med J. 2017;130:73-75.
    Abstract    



  31. OKON E, Stearns J, Durgam AK
    Tuberculous Psoas Abscess and Worsening Vascular Aneurysm; All from Bacillus Calmette-Guerin (BCG) Therapy?
    Am J Case Rep. 2017;18:810-812.
    Abstract    

    Abstract available

  32. MOLINA ESCUDERO R, Egui Rojo MA, de la Torre J, Paez Borda A, et al
    Back pain after varicocele embolization.
    Arch Esp Urol. 2017;70:623-624.
    Abstract    



  33. CHAPPIDI MR, Kates M, Sopko NA, Joice GA, et al
    Erectile Dysfunction Treatment Following Radical Cystoprostatectomy: Analysis of a Nationwide Insurance Claims Database.
    J Sex Med. 2017 Apr 28. pii: S1743-6095(17)30427.
    Abstract    

    Abstract available

  34. ABE T, Takada N, Kikuchi H, Matsumoto R, et al
    Perioperative morbidity and mortality of octogenarians treated by radical cystectomy-a multi-institutional retrospective study in Japan.
    Jpn J Clin Oncol. 2017;47:755-761.
    Abstract    

    Abstract available

  35. KOUBA EJ, Cheng L
    Understanding the Genetic Landscape of Small Cell Carcinoma of the Urinary Bladder and Implications for Diagnosis, Prognosis, and Treatment: A Review.
    JAMA Oncol. 2017;3:1570-1578.
    Abstract    

    Abstract available

  36. POTURALSKI MJ, Magi-Galluzzi C, Liu PS
    Squamous Cell Carcinoma of the Bladder Complicating Schistosomiasis: AIRP Best Cases in Radiologic-Pathologic Correlation.
    Radiographics. 2017;37:500-504.
    Abstract    



  37. SHAISH H, Newhouse JH
    Split-bolus CT urogram: Is less more?
    Abdom Radiol (NY). 2017;42:2119-2126.
    Abstract    

    Abstract available

  38. MIR SUBIAS A, Navarro Dourdil M, Charro Calvillo M, Sebastian Domingo JJ, et al
    Combined endoscopic resolution of iatrogenic stricture in an ureterosigmoidostomy.
    Rev Esp Enferm Dig. 2017;109:215-216.
    Abstract    

    Abstract available

  39. LIN SR, Yeh HC, Wang WJ, Ke HL, et al
    MiR-193b Mediates CEBPD-Induced Cisplatin Sensitization Through Targeting ETS1 and Cyclin D1 in Human Urothelial Carcinoma Cells.
    J Cell Biochem. 2017;118:1563-1573.
    Abstract    

    Abstract available

  40. NG KL, Chua CB
    Reiter's syndrome postintravesical Bacillus Calmette-Guerin instillations.
    Asian J Surg. 2017;40:163-165.
    Abstract    

    Abstract available

  41. KULKARNI JN, Agarwal H
    Transperitoneal vs. extraperitoneal radical cystectomy for bladder cancer: A retrospective study.
    Int Braz J Urol. 2017;43.
    Abstract    

    Abstract available

  42. YANG D, Du G, Xu A, Xi X, et al
    Expression of miR-149-3p inhibits proliferation, migration, and invasion of bladder cancer by targeting S100A4.
    Am J Cancer Res. 2017;7:2209-2219.
    Abstract    

    Abstract available

  43. KRIEGMAIR MC, Honeck P, Theuring M, Bolenz C, et al
    Wide-field autofluorescence-guided TUR-B for the detection of bladder cancer: a pilot study.
    World J Urol. 2017 Dec 6. pii: 10.1007/s00345-017-2147.
    Abstract    

    Abstract available

  44. BONFILL X, Martinez-Zapata MJ, Vernooij RWM, Sanchez MJ, et al
    Clinical interval and diagnostic characteristics in a cohort of bladder cancer patients in Spain: a multicenter observational study.
    BMC Res Notes. 2017;10:708.
    Abstract    

    Abstract available

  45. MOHAMMED A, Arastu Z
    Emerging concepts and spectrum of renal injury following Intravesical BCG for non-muscle invasive bladder cancer.
    BMC Urol. 2017;17:114.
    Abstract    

    Abstract available

  46. HU Y, Deng C, Zhang H, Zhang J, et al
    Long non-coding RNA XIST promotes cell growth and metastasis through regulating miR-139-5p mediated Wnt/beta-catenin signaling pathway in bladder cancer.
    Oncotarget. 2017;8:94554-94568.
    Abstract    

    Abstract available

  47. ZHANG Q, Wang C, Miao S, Li C, et al
    Enhancing E-cadherin expression via promoter-targeted miR-373 suppresses bladder cancer cells growth and metastasis.
    Oncotarget. 2017;8:93969-93983.
    Abstract    

    Abstract available

  48. SZYMANSKA B, Pawlik KJ, Sawicka E, Dembowski J, et al
    Evaluation of NMP22 in bladder cancer patients sensitive to environmental toxins.
    Adv Clin Exp Med. 2017;26:1069-1075.
    Abstract    

    Abstract available

  49. PASSOS GR, Camargo JA, Ferrari KL, Saad MJA, et al
    Intravesical Thalidomide boosts bacillus Calmette-Guerin (BCG) in non-muscle invasive bladder cancer treatment.
    Med Oncol. 2017;35:3.
    Abstract    

    Abstract available

  50. WONG JPC, Wei R, Lyu P, Tong OLH, et al
    Clinical and in vitro analysis of Osteopontin as a prognostic indicator and unveil its potential downstream targets in bladder cancer.
    Int J Biol Sci. 2017;13:1373-1386.
    Abstract    

    Abstract available

  51. D'ALOIA A, Berruti G, Costa B, Schiller C, et al
    RalGPS2 is involved in tunneling nanotubes formation in 5637 bladder cancer cells.
    Exp Cell Res. 2017 Dec 2. pii: S0014-4827(17)30639.
    Abstract    

    Abstract available

  52. CHIU SC, Chiu TL, Huang SY, Chang SF, et al
    Potential therapeutic effects of N-butylidenephthalide from Radix Angelica Sinensis (Danggui) in human bladder cancer cells.
    BMC Complement Altern Med. 2017;17:523.
    Abstract    

    Abstract available

  53. AZEVEDO R, Peixoto A, Gaiteiro C, Fernandes E, et al
    Over forty years of bladder cancer glycobiology: Where do glycans stand facing precision oncology?
    Oncotarget. 2017;8:91734-91764.
    Abstract    

    Abstract available

  54. SILVERS CR, Miyamoto H, Messing EM, Netto GJ, et al
    Characterization of urinary extracellular vesicle proteins in muscle-invasive bladder cancer.
    Oncotarget. 2017;8:91199-91208.
    Abstract    

    Abstract available

  55. HUANG L, Kong Q, Liu Z, Wang J, et al
    The Diagnostic Value of MR Imaging in Differentiating T Staging of Bladder Cancer: A Meta-Analysis.
    Radiology. 2017 Dec 4:171028. doi: 10.1148/radiol.2017171028.
    Abstract    

    Abstract available

  56. THOMA C
    Bladder cancer: Genomics of noninvasive disease.
    Nat Rev Urol. 2017 Dec 5. pii: nrurol.2017.207. doi: 10.1038/nrurol.2017.
    Abstract    



  57. PUNEET A, Balagopal N, Ginil K, Georgie M, et al
    Correlation of Transabdominal Ultrasonography and Cystoscopy in Follow-up of Patients with Non-muscle Invasive Bladder Cancer.
    Indian J Surg Oncol. 2017;8:548-553.
    Abstract    

    Abstract available

  58. SANLI O, Lotan Y
    Alternative therapies in patients with non-muscle invasive bladder cancer.
    Turk J Urol. 2017;43:414-424.
    Abstract    

    Abstract available

  59. ZHAO F, Ge YZ, Zhou LH, Xu LW, et al
    Identification of hub miRNA biomarkers for bladder cancer by weighted gene coexpression network analysis.
    Onco Targets Ther. 2017;10:5551-5559.
    Abstract    

    Abstract available

  60. CUI J, Chen S, Bo Q, Wang S, et al
    Preoperative prognostic nutritional index and nomogram predicting recurrence-free survival in patients with primary non-muscle-invasive bladder cancer without carcinoma in situ.
    Onco Targets Ther. 2017;10:5541-5550.
    Abstract    

    Abstract available

  61. TAKIZAWA T, Kojima M, Suzuki S, Osada T, et al
    New onset of myasthenia gravis after intravesical Bacillus Calmette-Guerin: A case report and literature review.
    Medicine (Baltimore). 2017;96:e8757.
    Abstract    

    Abstract available

  62. ZHOU N, Yuan Y, Long X, Wu C, et al
    Mutational signatures efficiently identify different mutational processes underlying cancers with similar somatic mutation spectra.
    Mutat Res. 2017;806:27-30.
    Abstract    

    Abstract available

  63. MALTE R, Kluth LA, Kaushik D, Boorjian SA, et al
    Frequency and prognostic significance of incidental prostate cancer at radical cystectomy: Results from an international retrospective study.
    Eur J Surg Oncol. 2017;43:2193-2199.
    Abstract    

    Abstract available

  64. CHEN CC, Huang CP, Tsai YT, Hseih TF, et al
    The Genomic Alterations of 5alpha-Reductases and Their Inhibitor Finasteride's Effect in Bladder Cancer.
    Anticancer Res. 2017;37:6893-6898.
    Abstract    

    Abstract available

  65. MINAMI S, Matsumoto K, Nagashio R, Hagiuda D, et al
    Analysis of Autoantibodies Related to Tumor Progression in Sera from Patients with High-grade Non-muscle-invasive Bladder Cancer.
    Anticancer Res. 2017;37:6705-6714.
    Abstract    

    Abstract available

  66. SYRING I, Weiten R, Muller T, Schmidt D, et al
    The Contrasting Role of the Mediator Subunit MED30 in the Progression of Bladder Cancer.
    Anticancer Res. 2017;37:6685-6695.
    Abstract    

    Abstract available

  67. MAURICE MJ, Kaouk JH
    Robotic radical perineal cystectomy and extended pelvic lymphadenectomy: initial investigation using a purpose-built single-port robotic system.
    BJU Int. 2017;120:881-884.
    Abstract    

    Abstract available

  68. WELTY CJ, Sanford TH, Wright JL, Carroll PR, et al
    The Cancer of the Bladder Risk Assessment (COBRA) score: Estimating mortality after radical cystectomy.
    Cancer. 2017;123:4574-4582.
    Abstract    

    Abstract available

  69. FANKHAUSER CD, Mostafid H
    Prevention of bladder cancer incidence and recurrence: nutrition and lifestyle.
    Curr Opin Urol. 2018;28:88-92.
    Abstract    

    Abstract available

  70. CHOI W, McConkey D
    Reply to Joshua A. Linscott, Angela B. Smith, and Jesse D. Sammon's Letter to the Editor re: Woonyoung Choi, Andrea Ochoa, David J. McConkey, et al. Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in The Cancer Genome Atl
    Eur Urol. 2017 Nov 23. pii: S0302-2838(17)30979.
    Abstract    



  71. ODDENS JR, de Reijke TM
    The Current State of Predicting Response on Bacillus Calmette-Guerin Treatment for Nonmuscle Invasive Bladder Cancer is Not Yet Useful for Patients but Attributes to Understanding Its Mechanisms of Action.
    Eur Urol. 2017 Nov 30. pii: S0302-2838(17)31006.
    Abstract    



  72. OHNO Y
    Editorial Comment to High neutrophil-to-lymphocyte ratio predicts worse overall survival in patients with advanced/metastatic urothelial bladder cancer.
    Int J Urol. 2017 Dec 7. doi: 10.1111/iju.13506.
    Abstract    



  73. DANESHMAND S, Patel S, Lotan Y, Pohar K, et al
    Efficacy and Safety of Blue Light Flexible Cystoscopy With Hexaminolevulinate (Hal) in the Surveillance of Bladder Cancer: A Phase Iii, Comparative, Multi-Center Study.
    J Urol. 2017 Dec 1. pii: S0022-5347(17)78004-4. doi: 10.1016/j.juro.2017.
    Abstract    

    Abstract available

  74. TAKAMURA T, Horinaka M, Yasuda S, Toriyama S, et al
    FGFR inhibitor BGJ398 and HDAC inhibitor OBP-801 synergistically inhibit cell growth and induce apoptosis in bladder cancer cells.
    Oncol Rep. 2017 Dec 1. doi: 10.3892/or.2017.6127.
    Abstract    

    Abstract available

  75. ALI P, Lefevre C, Perrouin-Verbe B, Le Normand L, et al
    [Bladder cancer in neurogenic patients: A retrospective study of management and follow-up].
    Prog Urol. 2017 Nov 22. pii: S1166-7087(17)30633.
    Abstract    

    Abstract available

  76. ZATTONI F, Palumbo V, Giannarini G, Crestani A, et al
    Perioperative Outcomes and Early Survival in Octogenarians Who Underwent Radical Cystectomy for Bladder Cancer.
    Urol Int. 2017 Dec 7. pii: 000478990. doi: 10.1159/000478990.
    Abstract    

    Abstract available

  77. XU H, Ma J, Chen Z, Yang J, et al
    Safety and Efficacy of en Bloc Transurethral Resection with 1.9Mum Vela Laser for Treatment of Non-Muscle-Invasive Bladder Cancer.
    Urology. 2017 Nov 30. pii: S0090-4295(17)31231.
    Abstract    

    Abstract available

  78. SHINDO T, Shimizu T, Nojima M, Niinuma T, et al
    Evaluation of Urinary DNA Methylation as a Marker for Recurrent Bladder Cancer: a Two-Center Prospective Study.
    Urology. 2017 Nov 28. pii: S0090-4295(17)31223.
    Abstract    

    Abstract available

  79. HUEBNER D, Rieger C, Bergmann R, Ullrich M, et al
    An orthotopic xenograft model for high-risk non-muscle invasive bladder cancer in mice: influence of mouse strain, tumor cell count, dwell time and bladder pretreatment.
    BMC Cancer. 2017;17:790.
    Abstract    

    Abstract available

  80. GROMOVA I, Svensson S, Gromov P, Moreira JMA, et al
    Identification of BLCAP as a novel STAT3 interaction partner in bladder cancer.
    PLoS One. 2017;12:e0188827.
    Abstract    

    Abstract available

  81. SASAKI N, Ishi K, Kudo N, Nakayama SMM, et al
    Spatial and temporal profile of cisplatin delivery by ultrasound-assisted intravesical chemotherapy in a bladder cancer model.
    PLoS One. 2017;12:e0188093.
    Abstract    

    Abstract available

  82. BOGNAR Z, Fekete K, Antus C, Hocsak E, et al
    Desethylamiodarone-A metabolite of amiodarone-Induces apoptosis on T24 human bladder cancer cells via multiple pathways.
    PLoS One. 2017;12:e0189470.
    Abstract    

    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design:


;